It was clear at TVT that tricuspid valve therapies will likely move ahead of new mitral therapies coming to market. Azeem Latib, MD, explained why.

Researchers tracked both short- and long-term outcomes, sharing their findings in the Journal of the American Heart Association.

Michael Mack, MD, a key pioneer in transcatheter aortic valve replacement (TAVR), explains the history of TAVR and where things are headed.

The study's authors reviewed data from more than 50,000 patients, presenting their findings in JACC: Clinical Electrophysiology.

Charles Davidson, MD, clinical chief of cardiology and medical director of the Bluhm Cardiovascular Institute, Northwestern University, explains what hospitals need to consider when starting a new structural heart program.